Q4 Earnings Analysis: Halozyme Therapeutics Performance

요약

“Halozyme Therapeutics reported Q4 revenues of $451.8 million, up 51.6% year-over-year, exceeding analyst expectations by 0.6%”
“Despite revenue beat, company missed EPS estimates and full-year guidance, causing stock to drop 22.9% to $62.07”
“Therapeutics sector showed strong Q4 performance with group revenues beating consensus by 7.1%, while Halozyme faces headwinds from drug pricing scrutiny”

Profit ▲ Debt high Cash neutral Valuation low Drawdown low Recent decline

Q4 실적 분석: 할로좀 테라퓨틱스 성과
할로좀 테라퓨틱스, Q4 매출 $451.8M 발표, 전년 대비 51.6% 증가, 애널리스트 예상치 0.6% 초과
매출 초과에도 불구하고 EPS 예상치 및 연간 가이던스 미달로 주가 22.9% 하락, $62.07 거래
치료제 업계, Q4 강한 실적 기록, 그룹 매출 컨센서스 7.1% 초과, 할로좀은 약가 규제 압박 직면

출처: TradingView
링크: https://www.tradingview.com/news/stockstory:82b840c8f094b:0-unpacking-q4-earnings-halozyme-therapeutics-nasdaq-halo-in-the-context-of-other-therapeutics-stocks/

소셜 공유 미리보기(OG) 전용 페이지입니다.